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Striatal oxidative damages and neuroinflammation 
correlate with progression and survival of Lewy body 
and Alzheimer diseases
Huifangjie Li, William C. Knight, Jinbin Xu*
Abstract  
Neurodegenerative diseases are a class of chronic and complex disorders featuring progressive loss of neurons in distinct brain areas. The 
mechanisms responsible for the disease progression in neurodegeneration are not fully illustrated. In this observational study, we have 
examined diverse biochemical parameters in the caudate and putamen of patients with Lewy body diseases (LBDs) and Alzheimer disease 
(AD), shedding some light on the involvement of oxidative damage and neuroinflammation in advanced neurodegeneration. We performed 
Spearman and Mantel-Cox analyses to investigate how oxidative stress and neuroinflammation exert comprehensive effects on disease 
progression and survival. Disease progression in LBDs correlated positively with poly (ADP-Ribose) and triggering receptors expressed on 
myeloid cell 2 levels in the striatum of LBD cohorts, indicating that potential parthanatos was a dominant feature of worsening disease 
progression and might contribute to switching microglial inflammatory phenotypes. Disease progression in AD corresponds negatively with 
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxo-dG) and myeloperoxidase concentrations in the striatum, suggesting that possible mitochondria 
dysfunction may be involved in the progression of AD via a mechanism of β-amyloid entering the mitochondria and subsequent free 
radicals generation. Patients with lower striatal 8-oxo-dG and myeloperoxidase levels had a survival advantage in AD. The age of onset also 
affected disease progression. Tissue requests for the postmortem biochemistry, genetics, and autoradiography studies were approved 
by the Washington University Alzheimer’s Disease Research Center (ADRC) Biospecimens Committee (ethics approval reference number: 
T1705, approval date: August 6, 2019). Recombinant DNA and Hazardous Research Materials were approved by the Washington University 
Environmental Health & Safety Biological Safety Committee (approval code: 3739, approval date: February 25, 2020). Radioactive Material 
Authorization was approved by the Washington University Environmental Health & Safety Radiation Safety Committee (approval code: 1056, 
approval date:  September 18, 2019). 
Key Words: Alzheimer disease; disease progression; Lewy body diseases; microglia; neurodegeneration; oxidative damage; striatum; survival
Chinese Library Classification No. R448; R741
https://doi.org/10.4103/1673-5374.322463
Date of submission: November 11, 2020 
Date of decision: January 4, 2021 
Date of acceptance: January 30, 2021 
Date of web publication: August 30, 2021 
Introduction 
Neurodegenerative diseases are disorders defined by 
progressive impairment of motor and/or cognitive function. 
Neurodegenerative diseases lead to severe and restlessly 
functional impairments for millions of people annually, 
affecting individuals’ life quality and happiness, burdening 
their families and caregivers, as well as raising many health-
related public concerns. There are no powerful therapies to 
prevent or reduce disease progression. However, available 
treatments can alleviate some symptoms, accompanied 
by ineffective consequences over time and final disruptive 
symptoms. One of the most significant challenges in 
neurodegenerative disease therapeutics is the clarification of 
clinically meaningful endpoints to measure progression. The 
pathogenesis of different neurodegenerative diseases shares 
specific characteristics, as featured with Alzheimer disease 
Department of Radiology, Washington University School of Medicine, St. Louis, MO, USA
*Correspondence to: Jinbin Xu, PhD, jinbinxu@wustl.edu. 
https://orcid.org/0000-0002-2120-8287 (Jinbin Xu)
Funding: This study was funded by NIH R01NS092865 and P30AG06644.
How to cite this article: Li H, Knight WC, Xu J (2022) Striatal oxidative damages and neuroinflammation correlate with progression and survival of Lewy body 
and Alzheimer diseases. Neural Regen Res 17(4):867-874. 
Research Article
Graphical Abstract Oxidative damages, neuroinflammation and neurodegeneration 
[Downloaded free from http://www.nrronline.org on Monday, September 20, 2021, IP: 128.252.174.220]
868  ｜NEURAL REGENERATION RESEARCH｜Vol 17｜No. 4｜April 2022
(AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis 
(ALS), and Huntington’s disease (Cho, 2010; Cummings, 2017; 
Katsuno et al., 2018). 
Increased levels of oxidative damages have been reported in 
all three stages of AD – mild cognitive impairment (MCI), early 
AD, and late-stage AD (Nunomura et al., 2001; Reed et al., 
2009a, b), supporting the hypothesis that oxidative damages 
may be one of the common pathological mechanisms at 
different AD stages. The decreases in the antioxidant enzyme 
activity may promote enlarged productions of free radicals, 
leading to increased oxidative damages in the nuclear 
and mitochondrial DNA during the progression from mild 
cognitive impairment to early AD/AD (Migliore et al., 2005; 
Guidi et al., 2006; Wang et al., 2006). Studies are consistent 
with the assumption that oxidative damage originates in 
the mild cognitive impairment brain is an early AD event 
and contributes to the disease progression (Stephan et al., 
2012). β-amyloid (Aβ) has been shown to enter mitochondria, 
generate free radicals, and cause oxidative damage in 
postmortem brain neurons from patients with AD and 
transgenic animal AD models (Cardoso et al., 2001; McLellan 
et al., 2003; Reddy, 2006). PD is the second most universal 
neurodegenerative disease featuring the aggregation of 
α-synuclein (α-syn) and the loss of dopamine neurons in the 
substantia nigra. As the resident macrophages and the chief 
immune defenders of the central nervous system (CNS), 
microglia protect against the subsequent dangers following 
the accumulation of α-syn via different activated phenotypes 
(Sanchez-Guajardo et al.,  2010). Microglia-mediated 
neuroinflammation and α-syn related disruption of cellular 
homeostasis promote each other; this positive feedback loop 
drives a worsening progression of neurodegeneration (Fellner 
et al., 2011; Schapansky et al., 2015). Pathologically, dying 
or dead dopaminergic neurons in PD release neuromelanin 
pigment, which could be one of the factors activating 
microglia (Wilms et al., 2003). Neuromelanin particles are 
phagocytized by microglia, inducing microglial activation, 
superoxide production, nitric oxide (NO), hydrogen peroxide 
(H2O2), and pro-inflammatory cytokines and chemokines 
(Zhang et al., 2011). Neuroinflammation and oxidative stress 
affect and potentiate each other, amplifying persistent and 
progressive neurodegeneration in PD. PD dementia (PDD), 
dementia with Lewy bodies (DLB), and PD have common 
clinical and neuropathological features and have been 
aggregated conceptually across the spectrum of Lewy body 
diseases (LBDs) (Lippa et al., 2007).
Recently, considerable advances in genome-wide association 
studies (GWASs) have classified genetic loci for Mendelian 
(or familial) neurodegenerative diseases (Gandhi and Wood, 
2010; Pihlstrøm et al., 2017). The dominant disorders are 
mostly sporadic and late-onset diseases caused by a complex 
of proteins misfolding and accumulating due to genetic 
mutations and environmental factors. Distinct biochemical 
entities in various brain areas have contributed to the 
understanding of neurodegenerative disease pathogenesis. 
The striatum contains two important sub-regions that 
receive input from different cortical regions – the caudate 
and putamen (Draganski et al., 2008). The caudate nucleus 
is implicated in diverse performances, including procedural 
learning and working memory (Seger and Cincotta, 2005; 
Hannan et al., 2010). The dorsal posterior putamen receives 
its principal input from the motor and sensorimotor cortices 
and contributes extensively to the regulation of motor circuits 
(Del Campo et al., 2016). 
Our laboratory has devoted considerable effort to the 
research of the striatum in patients with neurodegenerative 
diseases. We have found that the interactions between 
dopamine and oxidative damage play critical roles in 
advanced neurodegeneration (Li et al., 2020a). Chronic 
oxidative stress most likely leads to microglial phenotype 
changes between dystrophy and senescence (Han et al., 
2019; Xu et al., 2019). Interestingly, we have observed that 
oxidative damages, generated by misfolded tau proteins and 
dopamine metabolism, give rise to microglial dysfunction, 
which reversely reduces tau propagation (Li et al., 2020b). 
The physiological crosstalk between disease progression 
in neurodegenerative diseases and oxidative damage and 
neuroinflammation is still a lingering question. In this study, 
we analyzed diverse biochemical parameters, determined by 
our previous research and the clinical presentations of study 
patients, to provide a comprehensive attempt at addressing 
the possible correlations between striatal oxidative damages, 
inflammation, and neurodegenerative progression and 
survival.
 
Materials and Methods    
Ethics statement
Following local ethical committee protocols, patients 
gave written consent (Additional file 1) before cognitive 
impairment or responsible caregivers handed over approval 
antemortem or postmortem consent (Washington University 
Institutional Review Board, Washington University School of 
Medicine). Tissue requests for the postmortem biochemistry, 
genetics, and autoradiography studies were approved by the 
Washington University Alzheimer’s Disease Research Center 
(ADRC) Biospecimens Committee (ethics approval reference 
number: T1705, approval date: August 6, 2019).  Recombinant 
DNA and Hazardous Research Materials were approved by 
the Washington University Environmental Health & Safety 
Biological Safety Committee (approval code: 3739, approval 
date: February 25, 2020). Radioactive Material Authorization 
was approved by the Washington University Environmental 
Health & Safety Radiation Safety Committee (approval code: 
1056, approval date: September 18, 2019) (Additional file 2). 
The study involving human tissue samples was conducted in 
accordance with the Declaration of Helsinki.
Subjects
Clinically and neuropathologically well-analyzed human brain 
tissues were gained from the Knight ADRC and the Movement 
Disorders Center brain bank at Washington University School 
of Medicine. Initially, we collected tissues from a population 
of 10 PD patients (7 men, 3 women) aged 69–87 years at 
death (mean: 78 ± 2), 8 PDD patients (7 men, 1 woman) aged 
66–87 years at death (mean: 77 ± 3), 10 DLB patients (5 men, 
5 women) aged 69–89 years at death (mean: 81 ± 2), 27 AD 
patients (13 men, 14 women) aged 62–94 years at death 
(mean: 82 ± 2), and 10 age-matched congnitively control cases 
(6 men, 4 women) aged 72–93 years at death (mean: 83 ± 2) 
who passed away from non-neuronal causes. The arbitrary 
clinical distinction between DLB and PDD was achieved using 
the McKeith et al. criteria (Hughes et al., 1992; McKeith et al., 
2005). Dementia level was classified by the Clinical Dementia 
Rating (CDR) scale (Emre et al., 2007). Participants with a CDR 
≥ 1 were enrolled following their clinical evaluation using the 
CDR criteria for diagnosing dementia in PD. AD pathological 
changes were evaluated using Braak staging (Thal and 
Braak, 2005). Braak stages of amyloid-beta deposition are as 
follows: (A) the initial accumulates in the basal neocortex, 
(B) accumulations that extend into the adjacent areas of the 
neocortex, and (C) heavy accumulations throughout the entire 
cortex. Stages of neurofibrillary pathology are classified by 
their presentation in the transentorhinal (I–II), limbic (III–IV), 
and neocortical (V and VI) regions. There were no significant 
discrepancies in the average age and postmortem interval 
time across groups. All AD cases featured neurofibrillary 
tangles (NFTs) (V: 13 patients; VI: 14 patients) and significantly 
differed from those of the age-matched control cases (Average 
amyloid-beta: A; NFTs: II). Also, all LBDs showed NFTs. PD 
stages were defined by the Hoehn and Yahr scale (Hoehn 
and Yahr, 2001). Sustained response to levodopa (L-dopa) 
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is the supportive and positive criteria for LBDs, which were 
evaluated through L-dopa test (Abramsky et al., 1971). The 
clinical information and pathological characteristics are 
recapitulated in Table 1. 
Tissue collection
Brain tissues were harvested at the time of autopsy; 
subsequently, the right hemisphere was coronally sectioned 
and snap-frozen using liquid nitrogen vapor. Then, tissue 
blocks were preserved at –80°C. Frozen coronal sections (20 
µm) were prepared for autoradiography study. The caudate 
and putamen were carefully cut using a scalpel from adjacent 
cryosections and tested for biochemistry. 
Laboratory determinations of eight biochemical parameters
All tissue samples or tissue slices were prepared immediately 
before the assays. Concentrations of 8-oxo-7,8-dihydro-2′-
deoxyguanosine (8-oxo-dG), 8-oxo-7,8-dihydroguanosine 
(8-oxo-G), myeloperoxidase (MPO), and poly (ADP-Ribose) 
(PAR) in the samples were determined to evaluate oxidative 
damages developed in the striatum of patients and age-
matched controls. Levels of triggering receptors expressed 
on myeloid cell 2 (TREM2) in the striatum were analyzed 
to understand the possible microglial phenotype changes 
promoted by oxidative damages. Densities of translocator 
protein (TSPO) and tau fibrils were quantified to estimate 
the correlations between microglia dystrophy and tauopathy. 
Additionally, dopamine levels in the caudate and putamen 
were quantitatively measured. The detailed experimental 
procedures for biochemistry and quantitative autoradiography 
assays can be found in our previous reports (Li et al., 2020a, b). 
Methods are briefly described below. All data are summarized 
in Table 2. 
8-oxo-dG and 8-oxo-G quantification
Total DNA and RNA in the caudate and putamen of study 
brains were extracted separately using the Qiagen QIAamp 
DNA Mini Kit (Qiagen, Valencia, CA, USA; Cat# 51304) and 
the Qiagen RNeasy Plus Micro Kit (Qiagen; Cat# 74034). The 
concentrations of 8-oxo-dG and 8-oxo-G were determined 
separately using the OxiSelect oxidative DNA damage ELISA 
(Cell Biolabs, Inc., San Diego, CA, USA; Cat# STA-320) and the 
OxiSelect oxidative RNA damage ELISA kits (Cell Biolabs, Inc., 
Cat# STA-325-5).
MPO, PAR, and TREM2 quantification
Bra in  samples  were homogenized in  commerc ia l ly 
available lysis buffer (for MPO and TREM2, Fisher Scientific, 
895347, Pittsburgh, PA, USA) or RIPA buffer (for PAR), the 
supernatant was collected to determine the expression of 
MPO, PAR, and TREM2 in the caudate and putamen using 
the Myeloperoxidase Human ELISA kit (Abcam, ab119605, 
Cambridge, MA, USA), PAR ELISA kit (Cell Biolabs, Inc., XDN – 
5114, San Diego, CA, USA), and theTREM2 Human ELISA kit 
(Biomatik, EKU07882, Wilmington, DL, USA), respectively. 
Dopamine quantification
Brain samples were homogenized with PBS (Fisher Scientific; 
Cat# 50-983-207), and the supernatant was collected for 
quantification of dopamine levels in the caudate and putamen 
using the dopamine ELISA kit (BioVision, Inc., Milpitas, CA, 
USA, Cat# K4219).
TSPO and tau fibril quantification
The densit ies of TSPO and tau f ibri l  in the caudate 
and putamen from study brains were quantified using 
autoradiography, [3H]PBR28 (80 Ci/mmol, CAS Number: 
253307-72-1) and [3H]MK6240 (21.5 Ci/mmol, CAS Number: 
1841078-87-2) were chosen as radioligands, respectively. The 
TSPO gene was also genotyped to screen and exclude the low-
affinity binders for [3H]PBR28 autoradiography binding data 
analysis.   
Statistical analysis
Spearman’s correlation coefficient (rs) was calculated to assess 
the strength of the correlation between continuous variables. 
In this study, we estimated the correlations between patients’ 
clinical presentations: age at the onset of disease, disease 
progression, Braak NFT stage, Braak Aβ stage, PD stage, and 
8 biochemical parameters expressed in the caudate and 
putamen samples from patients with neurodegenerative 
diseases. Disease progression was calculated from the age 
Table 1 ｜ Demographic characteristics of the study subjects 
Control PD PDD DLB AD P
N 10 10 8 10 27
Male/female (n) 6/4 7/3 7/1 5/5 13/14 NA
Age (yr) 83±2 78±2 77±3 81±2 82±2 NA
PMI (h) 18.8±5 16.0±3.2 10.8±1.6 18.0±3.7 10.6±1.0 NA
Brain weight (g) 1326±60 1299±40 1346±41 1273±38 1127±47 NA
Age of onset (yr) 65±3 60±3 66±4 71±2 NA
Progression (yr) 14±1 16±3 14±3 10±1 NA
Braak NFT stage Stage 0: 1 Stage I: 5 Stage I: 3 Stage I: 7 Stage V: 13 *
Stage I: 2 Stage II: 2 Stage II: 2 Stage II: 2 Stage VI: 14
Stage II: 4 Stage III: 3 Stage III: 3 Stage V: 1 
Stage III: 3 
Braak Aβ stage All normal Normal: 3 Normal: 1 Normal: 1 All stage C NA
Stage A: 1 Stage A: 2 Stage A: 1
Stage B: 2 Stage B: 1 Stage B: 2
Stage C: 5 Stage C: 4 Stage C: 6
PD stage          All normal Stage 2: 2 Stage 2: 2 Stage 2.5: 2 All normal NA
Stage 2.5: 1 Stage 3: 3 Stage 3: 3
Stage 3: 4 Stage 4: 2 Stage 4: 2
Stage 4: 2 Stage 5: 1 Stage 5: 2
L-Dopa response Yes: 9 Yes: 6 Yes: 9
Modest: 1 Modest: 2 Modest: 1
Data are disclosed as the mean ± SEM. Braak Aβ stage: Braak amyloid-beta plaque stage; Braak NFT stage: Braak neurofibrillary tangle stage; PMI: Postmortem 
Interval; PD stage: Parkinson disease stage. *P < 0.05, vs. control.
[Downloaded free from http://www.nrronline.org on Monday, September 20, 2021, IP: 128.252.174.220]
870  ｜NEURAL REGENERATION RESEARCH｜Vol 17｜No. 4｜April 2022
of the onset to the age of death and expressed in years. We 
used a log-rank (Mantel-Cox) test to estimate the relationships 
between patient survival and the 8 biochemical parameters. 
Mantel-Cox curves for the patient’s survival were constructed 
according to high concentrations of the biochemical 
parameter (above the mean value) and low concentrations of 
the biochemical parameter (below the mean value). Statistical 
analyses were achieved using GraphPad Prism 6.0 (GraphPad 
Software Inc., San Diego, CA, USA; RRID: SCR_002798) for 
Windows and IBM SPSS Statistics version 23 (IBM, Armonk, 
NY, USA; RRID: SCR_002865). P < 0.05 was considered 
statistically significant. No sample size calculations, blinding, 
or randomizations were performed during the statistical 
analyses. 
Results
Demographic characteristics and biochemical parameters of 
study subjects
In this study, 65 participants, aged between 62 and 94, met 
the clinical diagnostic criteria: 10 PD subjects, 8 PDD subjects, 
10 DLB subjects, 27 AD subjects, and 10 healthy control 
subjects. Demographic characteristics of the disease and 
age-matched control groups are presented in Table 1. There 
were no significant differences in postmortem interval, age 
at death, brain weight, age at onset, and disease progression, 
suggesting that our results were not affected by these factors. 
Braak neurofibrillary tangle stage (NFT) stages observed in the 
AD group significantly differed from controls. 
Moreover, levels of nucleic acid oxidative species and 
dopamine, expressions of MPO, PAR, and TREM2, as well as 
densities of TSPO and tau fibrils in the caudate and putamen 
of the patients with neurodegenerative diseases and controls 
were identical (Table 2).
Correlations of biochemical parameters and disease 
progression in patients with neurodegenerative diseases
In the Spearman correlation analyses, PDD progression 
positively depended on the concentration of PAR in the 
caudate (rs = 0.786, P = 0.036; Figure 1A). We observed a 
positive correlation between the TREM2 levels in the putamen 
of PDD patients and disease progression (rs = 0.786, P = 
0.036; Figure 1B). Then we examined whether the microglial 
expression could be related to PDD disease progression. 
It appears that there was a negative correlation between 
TSPO levels in the putamen of the PDD group and disease 
progression (rs = –0.857, P = 0.014; Figure 1C). We further 
examined the LBD cohorts, and Spearman analyses revealed 
positive correlations between PAR concentration in the 
caudate of LBD brains and disease progression (rs = 0.539, 
P = 0.010; Figure 1D), as well as TREM2 expression in the 
putamen of LBD brains and disease progression (rs = 0.501, P = 
0.013; Figure 1E). Interestingly, we found significant negative 
correlations between 8-oxo-dG concentration in the putamen 
of AD brains and disease progression (rs = –0.453, P = 0.020; 
Figure 1F), as well as MPO levels in the caudate of AD brains 
and disease progression (rs = –0.594, P = 0.003; Figure 1G).
Correlations between the age of the onset and disease 
progression in patients with neurodegenerative diseases
T h o u g h t- p r o v o k i n g l y,  w e  fo u n d  t h a t  t h e  a g e  o f 
onset associated with disease progression in all  the 
neurodegenerative diseases studied, as shown in Figure 2. 
Spearman analyses uncovered negative correlations between 
the age of onset and disease progression in PD, PDD, DLB, 
and AD cohorts (Figure 2A–D). These results supported the 
hypothesis that the older the patients were, the more severe 
their clinical and neurophysiologic features, and that onset 
age mainly altered the rate of progression (Kempster et al., 
2010; Pagano et al., 2016).
Correlations between PD stage and biochemical parameters 
in patients with Lewy body diseases 
LBD patients were stratified into different PD stages according 
to the Hoehn and Yahr scale (Hoehn and Yahr, 2001). 
We investigated the relationships between biochemical 
parameters in the striatum and PD stages in LBD groups. A 
significant negative correlation was observed between PD 
stage and PAR concentration in the putamen of LBD brains 
(rs = –0.462, P = 0.023; Figure 3A). Additionally, a significant 
positive relationship was found between PD stage and TREM2 
concentration in the putamen of LBD cohorts (rs = 0.421, P = 
0.036; Figure 3B), which was in agreement with the positive 
correlation between disease progression and TREM2 levels in 
the putamen of LBD cases.
Impact of biochemical parameters in the striatum on the 
survival of patients with AD 
In the AD cohort, Mantel-Cox analyses revealed that patients 
with a lower 8-oxo-dG concentration in the putamen had a 
significant survival advantage over those with higher 8-oxo-dG 
levels (P = 0.0195; Figure 4A), indicating that DNA oxidative 
damage in the putamen played a critical role in patient 
survival. Besides, there was a significant difference in survival 
between AD cases with a higher MPO concentration in the 
caudate and those with lower MPO concentration in the same 
brain area (P = 0.0003; Figure 4B), suggesting MPO level in 
the caudate is a potential positive risk factor for survival in AD 
patients.
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(ng/g wet wt) MPO (pM/g) PAR (pM/g) TREM2 (ng/g) TSPO (fmol/mg) Tau (fmol/mg)
Control CA 20.7±2.58 33.1±4.31 12.3±6.99 5569±1536 5.11±1.97 160±35.5 732±140 458±82.6
PU 16.6±1.93 48.4±6.11 17.2± 5.08 3245±732 3.45±1.25 322±68.0 648±143 489±91.5
PD CA 11.2±1.46# 21.1±3.34 8.3±2.66 4654±1871 2.52±1.03# 217±37.7 178±24.6#### 120±20.4####
PU 16.6±1.78 21.1±3.64** 7.5±4.73 4824±2552 3.06±0.53 174±21.0 211±37.7### 121±24.4**
PDD CA 15.6±1.07 31.9±5.68** 9.8±3.38 4109±430 2.80±0.95# 316±60.4 270±40.1## 129±13.8####
PU 18.1±1.23 19.2±2.82 6.4±2.75 2802±373 2.34±0.64 219±34.9 276±27.6## 134±16.4**
DLB CA 16.2±1.23 23.9±2.92 19.0±10.3 2846±456 1.53±0.20# 239±32.5 225±49.9### 182±50.0####
PU 14.8±1.83 15.8±2.04**** 15.1±7.00 2582±432 2.63±0.37 220±30.0 202±41.2### 213±51.2*
AD CA 24.2±2.94 27.9±2.76 24.3±4.86 3754±434 10.1±1.97 225±29.2 1003±132 752±73.0
PU 13.9±0.73 40.4±3.12# 21.1±3.00 4316±728 2.17±0.24 344±50.0 825±106 716±41.8*###
Data are disclosed as the mean ± SEM. 8-oxo-dG: 8-oxo-7,8-dihydro-2'-deoxyguanosine; 8-oxo-G: 8-oxo-7,8-dihydroguanosine; AD: Alzheimer disease; CA: 
Caudate; DA: Dopamine; DLB: Dementia with Lewy body; LBDs: Lewy body diseases including PD, PDD, and DLB; MPO: myeloperoxidase; PAR: poly (ADP-Ribose); 
PD: Parkinson disease; PDD: Parkinson disease dementia; PU: Putamen; TREM2: Triggering receptors expressed on myeloid cell 2; TSPO: Translocator protein. 
*P < 0.05, **P < 0.01, ****P < 0.0001, vs. control; #P < 0.05, ##P < 0.01, ###P < 0.001, ####P < 0.0001, vs. LBDs (PD, PDD, and DLB).
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Figure 1 ｜ The correlations of biochemical parameters in the caudate and putamen of patients with diseases and disease progression.
(A) PAR concentration in the caudate of PDD vs. disease progression. (B) TREM2 concertation in the putamen of PDD vs. disease progression. (C) TSPO density 
in the putamen of PDD vs. disease progression. (D) PAR concentration in the caudate of LBDs vs. disease progression. (E) TREM2 concentration in the putamen 
of LBDs vs. disease progression. (F) 8-oxo-dG level in the putamen of AD vs. disease progression. (G) MPO concentration in the caudate of AD vs. disease 
progression. *P < 0.05, **P < 0.01. Sample size: PD, n = 10; PDD, n = 8; DLB, n = 10; AD, n = 27. 8-oxo-dG: 8-Oxo-7,8-dihydro-2′-deoxyguanosine; AD: Alzheimer 
disease; DLB: dementia with Lewy bodies; LBDs: Lewy body diseases; MPO: myeloperoxidase; PD: Parkinson disease; PDD: PD dementia; PAR: poly (ADP-ribose); 
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Figure 2 ｜ The correlations of the age of onset and disease progression. 
(A) PD. (B) PDD. (C) DLB. (D) AD. *P < 0.05, **P < 0.01. AD: Alzheimer disease; DLB: dementia with Lewy bodies; PD: Parkinson disease; PDD: PD dementia; rs: 
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Figure 3 ｜ The correlations between PD stage and biochemical parameters 
in the putamen of patients with LBD. 
(A) PAR concentration (pM/g). (B) TREM2 concentration (ng/g). *P < 0.05. rs: 
Spearman’s rank correlation coefficient. LBDs: Lewy body diseases; PAR: poly 
(ADP-ribose); PD: Parkinson disease; TREM2: triggering receptors expressed 
on myeloid cell 2.
Figure 4 ｜ Impact of biochemical parameters in the striatum on the AD patient survival. 
Mantel-Cox curve of patient survival according to high molecular level (above the mean value, blue line) and low molecular level (below the mean value, 
red line) in the caudate and putamen of AD brains. *P < 0.05, ***P < 0.001. 8-oxo-dG: 8-Oxo-7,8-dihydro-2′-deoxyguanosine; AD: Alzheimer disease; MPO: 
myeloperoxidase.
Discussion
Neurodegenerative diseases are disorders featured by 
progressive dysfunction of the motor and/or cognition. 
Pathogenically, these diseases share common characteristics 
– a vicious pathogenic cycle, including the accumulation of 
insoluble proteins, disturbance of the redox homeostasis, 
activation of glial cells, and death/loss of neurons. 
Disease progression in Lewy body diseases
LBDs are a family of neurodegenerative disorders identified by 
the presence of Lewy bodies, α-synuclein-positive inclusions 
in the brain. LBDs mainly consist of PD, DLB, and PDD. DLB 
is diagnosed as dementia that develops before or within 1 
year of PD, and PDD is dementia manifesting in the context 
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However, numerous metabolic and functional deficiencies 
developed in the early stage of PD brains are promoted by 
oxidative stress and mitochondrial abnormalities rather than 
Lewy pathology (Ferrer, 2009). 
We found significant positive correlations between disease 
progression and PAR concentrations in the caudate of PDD 
cases and LBD cohorts. Coincidently, PAR-dependent cell death 
has been described to be prevalent in slowly progressing 
dopaminergic neurodegeneration in PD mouse models (Lee et 
al., 2013). Parthanatos – one form of cell death – was named 
from the integration of “PAR” and “Thanatos”, Thanatos being 
the god of death in Greek mythology (Fatokun et al., 2014). 
Parthanatos can be generated by the accumulation of PAR 
accompanied by the overactivation of PAR polymerase-1. 
Excesses of PAR stimulates the mitochondrial release 
of apoptosis-inducing factor (AIF), which, together with 
macrophage migration inhibitory factor, enters the nucleus 
and cleaves genomic DNA into large fragments (Park et al., 
2020). Aminoacyl-tRNA synthetase complex interacting 
multifunctional protein-2 has been reported to be critically 
involved in the dopaminergic cell death mediated by 
parthanatos, indicating that PAR polymerase-1 inhibition 
may practically slow the progression of Parkinson disease 
(Lee et al., 2013). On the other hand, overactivation of PAR 
polymerase-1 plays a crucial role in causing deterioration 
of the blood-brain barrier, whose defense slows down PD 
progression (Wu et al., 2014). 
Impressively, in contrast to the caudate results, we found a 
significant negative correlation between the PD stage and PAR 
concentration in the putamen of LBD brains. PD stages are 
defined by the Hoehn and Yahr Scale (Hoehn and Yahr, 2001). 
Patients’ motor symptoms and secondary physical features get 
worse as the disease progresses, as well as the advanced PD 
stages, which can be proved further by the significant positive 
correlation between PD stage and disease progression in 
the LBD patients (Additional Figure 1; rs = 0.479, P = 0.015). 
These results might indicate asymmetric biochemical and 
pathological changes in the caudate and putamen of patients 
with LBDs. The putamen of PD patients has been defined with 
more deficiency in dopamine storage capacity, decreased 
dopaminergic projections from the substantia nigra, increased 
dopamine D2 receptor, and loss/or lower benzodiazepine 
receptor and muscarinic receptor when compared with the 
caudate of PD and AD cases (Griffiths et al., 1994; Rinne et al., 
1995; Otsuka et al., 1996; Kumakura et al., 2006). We firstly 
reported the PAR concentrations in the caudate and putamen 
of patients with neurodegenerative diseases. However, by 
virtue of the small sample size for these groups, asymmetric 
alterations in the PAR levels of the caudate and putamen still 
need to be more robustly elucidated in further studies. 
It was remarkable to find significant positive correlations 
between disease progression/PD stage and TREM2 expressions 
in the putamen of PDD cases and the LBD cohorts. TREM2 
is expressed entirely by microglia within the central nervous 
system, acting as a primary immune checkpoint that modulates 
the microglial homeostatic pathway (Jay et al., 2017). TREM2 
upregulation in the late-stage of AD progression was reported 
in postmortem brains (Perez et al., 2017). Emerging evidence 
shows that microglia can polarize into classic inflammatory M1 
and immunosuppressive M2 phenotypes. TREM2 is beneficial 
for switching between the M1 and M2 microglial phenotypes 
and is especially essential for M2 microglia polarization (Belloli 
et al., 2017). In a previous report, diverse stages of disease-
associated-microglia were modulated independently and/or 
dependently by TREM2. This finding, along with our results, 
suggests high microglial heterogeneity in individual patients 
during the disease progression or stages (Masuda et al., 2020). 
Upregulation of TREM2 levels in the late disease progression 
seems to be a compensatory attempt of TREM2 to alleviate 
the microglial over-activation or ameliorate dystrophic, 
or senescent, microglial types (Zhang et al., 2018). This 
hypothesis was supported further by the significant negative 
correlation between disease progression and TSPO density 
in the putamen of PDD patients – a marker of brain microglia 
activation.
Disease progression and survival in AD
Information obtained from studies of familial AD models 
might also be applicable to sporadic AD, where increased 
age-dependent oxidative damages have been clarified 
as a potential key factor leading to a more rapid disease 
progress ion  (Melov,  2004;  Manczak  et  a l . ,  2005) . 
Mechanistically, Aβ enters mitochondria and generates free 
radicals, leading to oxidative damages in postmortem AD brain 
cells and, in turn, disrupts mitochondrial function (McLellan 
et al., 2003; Crouch et al., 2005). Therefore, mitochondrial 
dysfunction is tightly involved in the onset and progression 
of AD, which might be an alternative therapeutic target (Yang 
et al., 2020). The significant negative correlations between 
disease progression and 8-oxo-dG concentration in the 
putamen, as well as MPO levels in the caudate of patients with 
AD, lends evidence for this hypothesis. 
8-oxo-dG, the guanine oxidation product of DNA, can cause 
GC to AT transversions. The increased DNA damage and 
decreased DNA repair found in AD patients have been closely 
correlated to the deficiency in the nonhomologous end joining 
repair pathway (De Zio et al., 2012). Studies conducted up to 
now are consistent with the assumption that oxidative stress 
initiated early in AD brains may contribute to AD progression. 
Survival analyses of AD cases point towards an inherently 
higher risk of mortality in AD patients with a higher 8-oxo-dG 
concentration in the putamen. 
The MPO protein, released from azurophilic granules, can 
generate cytotoxic reactive oxygen species (ROS) and can 
also form neutrophil extracellular traps when combined with 
other neutrophil proteins (Aratani, 2018). Clinical studies have 
revealed that alterations in the neutrophil activity and levels 
of ROS and neutrophil extracellular traps are associated with 
AD disease progression (Vitte et al., 2004; Dong et al., 2018). 
Pathologically, MPO has been found in the frontal cortex and 
hippocampus of AD brains, co-localized with amyloid plaques 
and neurofibrillary tangles (NFTs). Moreover, higher MPO 
concentration in the blood might be relevant to elevated 
levels of oxidative stress markers in AD patient blood samples 
(Gellhaar et al., 2017; Swardfager et al., 2017). The Mantel-
Cox curve of patient’s survivals showed that AD patients with 
a lower MPO level in the caudate had a survival advantage 
over those with a higher level. 
ROS reacts with cellular components and leads to disruption 
of redox homeostasis and cell death. ROS also accelerates 
the disease progression and ultimately influences life span. 
Moreover, survival time was linked with age of diagnosis, living 
status, medication treatment, and epilepsy history. 
The correlation of age of onset and disease progression
Depending on the age of onset, PD patients have been 
classified into four phenotypes in a new investigation: 
younger than 50, 50–59, 60–69, and older than or equal 
to 70 years (Pagano et al., 2016). The older the patients 
were, the more severe their clinical presentations, including 
motor dysfunction and cognitive impairment. This might be 
explained by their more significant dopaminergic deficiency 
and increased reduction of α-syn and total tau proteins in 
their cerebrospinal fluid, indicating that onset age closely 
affects the rate of disease progression. On the contrary, early-
onset AD – defined by a young age of onset (< 65 years) – 
presents with worse neurodegeneration and a more rapid 
disease progression, probably due to chronic microglial over-
activation and abnormal glucose hypometabolism (Tondo 
et al., 2020). Intriguingly, in this study, we found significant 
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negative correlations between age of onset and disease 
progression in PD, PDD, DLB, and AD. These trends seem to 
indicate that the younger age of onset, the longer survival 
time patients experience. However, the common mechanism 
and therapy target for slowing disease progression needs to 
be explored. 
The coupling found in our analysis between the patients’ 
biochemical parameters and disease progression and survival 
is interesting, although limited by the subject numbers and the 
brain regions studied. Thus, the more systematic, extensive, 
and cross-sectional investigations in a larger population of 
patients with different brain regions would further validate 
bonafide biomarkers and facilitate understanding of the 
mechanisms involved in disease progression. Postmortem 
studies using the end-stage cases may not reflect the 
biomarker changes of the clinical phases. Therefore, our 
results need to be further confirmed by additional clinical 
trials and compared with antemortem cerebrospinal fluid and 
plasma oxidative damage measures. 
Conclusions
Using 8 biochemical parameters examined from the caudate 
and putamen of patients with neurodegenerative diseases, 
we have performed Spearman and Mantel-Cox analyses 
to explore the correlations between these biochemical 
parameters, disease progression, and survival. These results 
supported the concept that the two characteristic features of 
neurodegenerative diseases, disruption of redox homeostasis 
and neuroinflammation, can potentiate each other and lead 
to the loss and dysfunction of neurons that affect disease 
progression. Furthermore, we found that older age of onset 
was associated with a faster disease progression in the 
neurodegenerative cohorts studied. The apparent lack of 
large cohort recruitments hardly supported some degree of 
generalizability of our findings. Essential future directions 
for research could include studies examining factors that 
may influence the progression and survival rates reported in 
the present study with larger cohorts of late-onset diseases 
and early-onset diseases induced by genetic mutations. 
Although the exact detailed mechanisms remain clarified, 
our observations might help understand these diseases’ 
progression and survival rates.
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Additional Figure 1 Correlations between PD stage and disease progression in the patients with Lewy body
diseases.
*P < 0.05. rs: the Spearman's rank correlation coefficient. PD: Parkinson disease.
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